Trial · NCT04514458
Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure
NCT04514458, Not applicable, Completed, Yale University; results first posted 2025-07-01
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure. Trials, record NCT04514458. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04514458
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure
- NCT number
- NCT04514458
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 1,410 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
- First posted
- 2020-08-17
- Last updated
- 2025-07-01
- Results first posted
- 2025-07-01
- Limitations and caveats
Limitations include being conducted at a single health system, that it primarily examined an increase in medication initiation rather than up-titration of dosing, that the alert has only been created and used in the Epic EHR framework, and that the alert was tested during a time when there were coordinated and intensive efforts across the study site to improve medical therapy for heart failure, which is reflected by increases in HFrEF therapies in the usual care arm of the study.
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | Assessed from the date of randomization to 30 days post-randomization | Assessed as an increase in the number of prescribed targeted evidence-based therapies for HFrEF, including beta-blockers, ACEi, ARBs, ARNIs, MRAs, and SGLT2is. |
| Secondary | Percentage of Patients on Beta Blockers | Assessed from the date of randomization to 30 days post-randomization | Assessed as the number of patients with prescribed beta blockers |
| Secondary | Percentage of Patients on ACE Inhibitors | Assessed from the date of randomization to 30 days post-randomization | Assessed as the number of patients with a prescribed ACEi |
| Secondary | Percentage of Patients on ARBs | Assessed from the date of randomization to 30 days post-randomization | Assessed as the number of patients with a prescribed ARB |
| Secondary | Percentage of Patients on ARNIs | Assessed from the date of randomization to 30 days post-randomization | Assessed as the number of patients with a prescribed ARNI |
| Secondary | Percentage of Patients on MRAs | Assessed from the date of randomization to 30 days post-randomization | Assessed as the number of patients with a prescribed MRA |
| Secondary | Percentage of Patients on SGLT2 Inhibitors | Assessed from the date of randomization to 30 days post-randomization | Assessed as the number of patients with a prescribed SGLT2i |
| Secondary | Rate of One-year All-cause Mortality | Assessed from the date of randomization to the date of death from any cause, up to 365 days post-randomization | Assessed as the number of patients who expired from randomization up to one year from any cause. |
| Secondary | Rate of 30-day Hospital Admission | Assessed from the date of randomization to the date of hospital admission, up to 30 days post-randomization | Number of participants with a hospitalization within 30 days of randomization |
| Secondary | Rate of 30-day All-cause Emergency Department Visits | Assessed from the date of randomization to the date of ED/ER admission, up to 30 days post-randomization | Number of participants with an emergency department visit within 30 days of randomization. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | Assessed from the date of randomization to 30 days post-randomization | Observed in patient subjects only. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Patients on Beta Blockers | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on ACE Inhibitors | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on ARBs | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on ARNIs | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on MRAs | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Patients on SGLT2 Inhibitors | Assessed from the date of randomization to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of One-year All-cause Mortality | Assessed from the date of randomization to the date of death from any cause, up to 365 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of 30-day Hospital Admission | Assessed from the date of randomization to the date of hospital admission, up to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rate of 30-day All-cause Emergency Department Visits | Assessed from the date of randomization to the date of ED/ER admission, up to 30 days post-randomization | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 outcomesResults by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | EHR-based Alert | 176 | Participants | ||
| Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | Usual Care | 117 | Participants | ||
| Percentage of Patients on Beta Blockers | EHR-based Alert | 606 | Participants | ||
| Percentage of Patients on Beta Blockers | Usual Care | 521 | Participants | ||
| Percentage of Patients on ACE Inhibitors | EHR-based Alert | 83 | Participants | ||
| Percentage of Patients on ACE Inhibitors | Usual Care | 92 | Participants | ||
| Percentage of Patients on ARBs | EHR-based Alert | 111 | Participants | ||
| Percentage of Patients on ARBs | Usual Care | 85 | Participants | ||
| Percentage of Patients on ARNIs | EHR-based Alert | 334 | Participants | ||
| Percentage of Patients on ARNIs | Usual Care | 285 | Participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | EHR-based Alert | 735 | |
| Overall Study | STARTED | Usual Care | 675 | |
| Overall Study | Patient Subjects Enrolled | EHR-based Alert | 685 | |
| Overall Study | Patient Subjects Enrolled | Usual Care | 625 | |
| Overall Study | Provider Subjects Enrolled | EHR-based Alert | 50 | |
| Overall Study | Provider Subjects Enrolled | Usual Care | 50 | |
| Overall Study | COMPLETED | EHR-based Alert | 731 | |
| Overall Study | COMPLETED | Usual Care | 672 | |
| Overall Study | NOT COMPLETED | EHR-based Alert | 4 | |
| Overall Study | NOT COMPLETED | Usual Care | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | EHR-based Alert | 75 | 685 |
| Total, all-cause mortality | Usual Care | 68 | 625 |
| Total, other adverse events | EHR-based Alert | 0 | 685 |
| Total, other adverse events | Usual Care | 0 | 625 |
| Total, serious adverse events | EHR-based Alert | 0 | 685 |
| Total, serious adverse events | Usual Care | 0 | 625 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons12
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| EHR-based Alert vs Usual Care: Percentage of Patients on ARBs | Trial comparisons |
| EHR-based Alert vs Usual Care: Percentage of Patients on Beta Blockers | Trial comparisons |
| EHR-based Alert vs Usual Care: Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy | Trial comparisons |
| EHR-based Alert vs Usual Care: Percentage of Patients on MRAs | Trial comparisons |
| EHR-based Alert vs Usual Care: Percentage of Patients on ARNIs | Trial comparisons |
| EHR-based Alert vs Usual Care: Percentage of Patients on ACE Inhibitors | Trial comparisons |
| EHR-based Alert vs Usual Care: Rate of One-year All-cause Mortality | Trial comparisons |
| EHR-based Alert vs Usual Care: Percentage of Patients on SGLT2 Inhibitors | Trial comparisons |
| EHR-based Alert vs Usual Care: deaths from any cause | Trial comparisons |
| EHR-based Alert vs Usual Care: Rate of 30-day All-cause Emergency Department Visits | Trial comparisons |
1 to 10 of 12
See all 12 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04514458
GET https://conductscience.org/api/trials/v1/NCT04514458/registered